Literature DB >> 2543100

Surgical treatment of multiple primary lung cancers.

A F Verhagen1, H J van de Wal, A L Cox, L K Lacquet.   

Abstract

Multiple primary lung cancers are now being recognized more frequently. Out of 1004 patients with a resected lung cancer, 32 (3.2%) presented a second primary and two of them a third primary lung cancer. A synchronous (S) primary was present in 7 and a metachronous (M) primary was present in 25. The histology was different in 1/7 with a S. and in 6/25 with a M. cancer. In all cases the cancer was located in another segment, lobe or lung. Out of the 7 with a S. cancer, 3 had a one stage and 4 a staged resection; out of the 25 with a M. cancer, 3 were treated by chemotherapy, 22 had a 2nd and 1 a 3rd operation to remove a new cancer. The mean time interval in M. cancer was 4 years, 8 months and was longer for adeno- (8 years) than for squamous cell carcinomas (4 years), longer for a contralateral cancer (6 years, 7 months) and longer for mild smokers (5 years, 1 month). The early mortality (10.3%) was 0/7 for S. and 3/22 for M. cancers. The three and five years actuarial survival of operated patients was 67% and 25% for S. and 43% and 31% for M. cancers. Survival is positively affected by a resection interval of more than 3 years and by 3 instead of 2 remaining lobes after the second resection. In conclusion a close follow-up of operated lung cancer patients is necessary and aggressive surgical approach is indicated for a new primary cancer.

Entities:  

Mesh:

Year:  1989        PMID: 2543100     DOI: 10.1055/s-2007-1013919

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  8 in total

1.  Synchronous growth of triple lung cancer.

Authors:  A Motohiro; T Matsumoto; S Ienaga
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

2.  [The effectiveness of standardized follow-up studies after resection of non-small cell bronchial carcinoma].

Authors:  H U Zieren; J M Müller; D Petermann; H Pichlmaier
Journal:  Langenbecks Arch Chir       Date:  1994

3.  Suggestive synchronous triple squamous cell carcinoma of the lung in the same lobe.

Authors:  Riki Okita; Katsuhiko Shimizu; Takeshi Mimura; Yoshihiro Miyata; Morihito Okada; Koji Arihiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2010-08-12

4.  Prior Treatment for Non-small Cell Lung Cancer Is Associated With Improved Survival in Patients who Undergo Definitive Stereotactic Body Radiation Therapy for a Subsequent Lung Malignancy: A Retrospective Multivariate and Matched Pair Analysis.

Authors:  Mark K Farrugia; Sung Jun Ma; Mark W Hennon; Chukwumere E Nwogu; Elisabeth U Dexter; Anthony L Picone; Todd L Demmy; Jorge A Gomez-Suescun; Simon Fung-Kee-Fung; Sai S Yendamuri; Anurag K Singh
Journal:  Am J Clin Oncol       Date:  2021-01-01       Impact factor: 2.339

5.  "Different trend" in multiple primary lung cancer and intrapulmonary metastasis.

Authors:  Cheng Shen; Xin Wang; Long Tian; Yubin Zhou; Dali Chen; Heng Du; Weiya Wang; Lunxu Liu; Guowei Che
Journal:  Eur J Med Res       Date:  2015-02-20       Impact factor: 2.175

6.  A Rare Case Of Synchronous Multiple Primary Lung Cancer: Squamous Cell Cancer And Small Cell Lung Cancer.

Authors:  Luxi Jiang; Xiangxin Zheng; Shengchang Wu; Jie Zhang; Guoqing Ru; Yaqing Li
Journal:  Onco Targets Ther       Date:  2019-10-24       Impact factor: 4.147

7.  Genomic profiles and transcriptomic microenvironments in 2 patients with synchronous lung adenocarcinoma and lung squamous cell carcinoma: a case report.

Authors:  Licheng Wu; Poming Kang; Shaolin Tao; Zhikun Zhao; Longyun Chen; Yajie Xiao; Qunyou Tan
Journal:  BMC Med Genomics       Date:  2020-01-31       Impact factor: 3.063

8.  "Unique trend" and "contradictory trend" in discrimination of primary synchronous lung cancer and metastatic lung cancer.

Authors:  Cheng Shen; Huan Xu; Lunxu Liu; Yubin Zhou; Dali Chen; Heng Du; Zhaojie Han; Guowei Che
Journal:  BMC Cancer       Date:  2013-10-09       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.